Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Breast augmentation
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Medical complications=== The plastic surgical emplacement of breast-implant devices, either for [[breast reconstruction]] or for [[Plastic surgery|aesthetic purpose]], presents the same health risks common to [[surgery]], such as adverse reaction to [[anesthesia]], [[Breast hematoma|hematoma]] (post-operative bleeding), [[seroma]] (fluid accumulation), incision-site breakdown (wound infection).<ref>{{Cite web |title=Complications and Risks of mammoplasty {{!}} What to do? |url=https://drzykov.com/articles/complications-mammoplasty.html |access-date=2024-04-11 |website=drzykov.com |language=en}}</ref> Complications specific to breast augmentation include breast pain, altered sensation, impeded breast-feeding function, visible wrinkling, asymmetry, thinning of the breast tissue, and [[symmastia]], the "bread loafing" of the bust that interrupts the natural plane between the breasts. Specific treatments for the complications of indwelling breast implants{{snd}}[[capsular contracture]] and capsular rupture{{snd}}are periodic [[MRI]] monitoring and physical examinations. Furthermore, [[Complications (medical)|complications]] and re-operations related to the implantation surgery, and to [[Tissue expansion|tissue expanders]] (implant placeholders during surgery) can cause unfavorable [[scar]]ring in approximately 6β7% of the patients. <ref name = AUG_2006 /><ref name=MMG_2006>{{cite web|title=Important Information for Augmentation Patients About Mentor MemoryGel Silicone Gel-Filled Breast Implants |url=https://www.fda.gov/cdrh/pdf3/p030053d.pdf |date=2006-11-03 |work=fda.gov |access-date=2007-05-04 |url-status=dead |archive-url=https://web.archive.org/web/20080308085812/https://www.fda.gov/cdrh/pdf3/p030053d.pdf |archive-date=March 8, 2008 }}</ref><ref name=FDA_2004d>{{cite web|title=Saline-Filled Breast Implant Surgery: Making An Informed Decision (Mentor Corporation) |work=FDA Breast Implant Consumer Handbook β 2004 |url=https://www.fda.gov/cdrh/breastimplants/labeling/mentor_patient_labeling_5900.html |date=2004-01-13 |access-date=2007-05-04 |url-status=dead |archive-url=https://web.archive.org/web/20061126155432/https://www.fda.gov/cdrh/breastimplants/labeling/mentor_patient_labeling_5900.html |archive-date=November 26, 2006 }}</ref> Statistically, 20% of women who underwent cosmetic implantation, and 50% of women who underwent breast reconstruction implantation, required their explantation at the 10-year mark.<ref>[https://web.archive.org/web/20110625013310/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm260235.htm FDA provides updated safety data on silicone gel-filled breast implants]. Fda.gov (2011-06-22). Retrieved on 2012-07-15.</ref> In 2019, a direct link was identified between Allergan BIOCELL textured breast implants of Allergan and the breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system. FDA recalled all Allergan BIOCELL implants.<ref>{{Cite journal|last=Health|first=Center for Devices and Radiological|date=2019-12-20|title=Allergan Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer|url=https://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer|archive-url=https://web.archive.org/web/20190924131504/https://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer|url-status=dead|archive-date=September 24, 2019|journal=FDA|language=en}}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)